CVAD regimen
|
WikiDoc Resources for CVAD regimen |
|
Articles |
|---|
|
Most recent articles on CVAD regimen Most cited articles on CVAD regimen |
|
Media |
|
Powerpoint slides on CVAD regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CVAD regimen at Clinical Trials.gov Clinical Trials on CVAD regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CVAD regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CVAD regimen Discussion groups on CVAD regimen Patient Handouts on CVAD regimen Directions to Hospitals Treating CVAD regimen Risk calculators and risk factors for CVAD regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CVAD regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: CHOD; CTX/DM/DOX/VCR; CVAD; Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine
Overview
CVAD regimen refers to a regimen consisting of cyclophosphamide, vincristine, adriamycin (Doxorubicin), dexamethasone used to treat Multiple myeloma.[1]
Regimen
CCyclophosphamide
VVincristine (Oncovin)
ADoxorubicin (Adriamycin, Hydroxydaunorubicin)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N; et al. (2012). "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results". Haematologica. 97 (3): 442–50. doi:10.3324/haematol.2011.043372. PMC 3291601. PMID 22058209.